BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:[ U.S. CDMRP –Technology/Therapeutic Development Award for Emerg
 ing Viral Diseases and Respiratory Health | Research Funding ]
DTSTART;VALUE=DATE:20200528
DTSTAMP:20260510T105638Z
UID:0eb01c3ba7b054e86de167fd3a0147546a1ea8e3bf1b20d83c28a2c6
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the Peer-Reviewed M
 edical Research Program (PRMRP) Awards. The PRMRP Technology/Therapeutic D
 evelopment Award for Emerging Viral Diseases and Respiratory Health is a p
 roduct-driven award mechanism intended to provide support for the translat
 ion of promising preclinical findings into products for clinical applicati
 ons\, including prevention\, detection\, diagnosis\, treatment\, or improv
 ement of quality of life. These products should be relevant to Emerging Vi
 ral Diseases and/or Respiratory Health\, particularly as they relate to CO
 VID-19\, as described in the list of Topic Areas at the end of this announ
 cement.\n\nRelevance to the healthcare needs of military Service members\,
  Veterans\, military beneficiaries\, and/or the American public is a key f
 eature of this award. Applications are required to include an explanation 
 of how the proposed project has relevance to military health.\n\nFunding: 
        max. $4’000’000\n\nDuration:      4 years\n\nEligibil
 ity: Applicants from international organizations or institutions are eligi
 ble to apply\, and there are no citizenship restrictions. PI applicants mu
 st be independent investigators at or above the level of Assistant Profess
 or (or equivalent).\n\nHow to Apply: Pre-applications are submitted throug
 h the eBRAP platform. They should contain contact information\, a letter o
 f intent\, and a list of collaborators and key personnel as suggested on t
 he platform. Full applications (by invitation) will be made via a Grants.g
 ov workspace. Full application packages can be downloaded from Grants.gov 
 at any time.\n\nPre-Application Deadline: 28-May-2020\, 5:00 p.m. EST\nFul
 l Application Deadline: 12-Jun-2020\, 11:59 p.m. EST\n\nGrants.gov Funding
  Opportunity Number: W81XWH-20-PRMRP-TTDA-COV\n\nFurther information\n\n	T
 o see the program announcement\, navigate to the search page on Grants.gov
  and search for the Opportunity Number W81XWH-20-PRMRP-TTDA-COV\n	For ques
 tions about the eBRAP or Grants.gov platforms\, contact the Research Offic
 e.\n\n\nFY20 Topic Areas: Emerging Viral Diseases and Respiratory Health\n
 \n\n	On demand identification\, isolation\, characterization and manufactu
 ring of antibodies (monoclonal or polyclonal) from peripheral blood mononu
 clear cells (PBMCs) collected from patients with coronavirus disease 2019 
 (COVID-19).\n	Development of a wearable sensor that provides real-time dia
 gnostics that can be used as a point of care for emerging viral diseases t
 o predict illness before onset of symptoms.\n	Surveillance and predictive 
 modeling tools that leverage artificial intelligence approaches to predict
  outbreaks and epidemics and support strategies for mitigating the threat 
 of COVID-19.\n	Triage of care for COVID-19 patients requiring access to re
 source-intensive interventions.\n	Research to understand novel molecular a
 nd biological mechanisms of COVID-19 health impacts (e.g.\, microbiome) an
 d identification/validation of biochemical\, physiological\, or combined b
 iomarkers for evaluating short- and long-term health impacts from COVID-19
 .\n	Research to determine direct and indirect impacts of COVID-19 on milit
 ary readiness and unit climate\; interpersonal/family dynamics\; behaviora
 l and mental health issues such as depression\, suicide\, anxiety\, and lo
 neliness and other key risk factors such as substance abuse and risky heal
 th-related behaviors.\n	Research on the etiology and prevention of acute r
 espiratory distress syndrome (ARDS) caused by host responses to coronaviru
 ses\, particularly COVID-19.\n	Development of improved methods for assessi
 ng and treating lung injury due to coronaviruses\, particularly COVID-19.\
 n	Novel and/or innovative detection technologies or therapeutics to reduce
  the incidence and/or severity of ARDS and/or other lung injury secondary 
 to coronaviruses\, particularly COVID-19.\n	Development of biomarker metri
 cs to associate the long-term health outcomes of virus-induced ARDS with d
 egradation of physiological and physical performance.\n	Ventilation and Ex
 tracorporeal Life Support approaches and technologies to support lung func
 tion or airway management in response to COVID-19 that increase survivabil
 ity and/or minimize care provider burden or exposure.\n	Pharmacological an
 d biologic interventions for COVID-19 induced complications\, including AR
 DS and related sequelae.\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR